{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    51,
    53,
    54,
    56,
    58,
    59,
    60,
    61,
    62,
    68,
    69,
    70,
    73,
    76,
    79,
    98,
    99,
    101
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study treatment"
      },
      {
        "id": "anchor_llm_1",
        "definition": "The date on which the patient is assigned to a treatment group through the randomization process",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "OS, defined as the time from randomization to death from any cause"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_3",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P21D",
        "sourceText": "21-day cycle"
      },
      {
        "id": "rep_cycle_4",
        "type": "Cycle",
        "cycleLength": "P3D",
        "sourceText": "3-week cycle"
      },
      {
        "id": "rep_cycle_15",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_18",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease \nprogression"
      },
      {
        "id": "rep_cycle_19",
        "type": "Cycle",
        "exitCondition": "Unacceptable toxicity",
        "sourceText": "until unacceptable toxicity"
      },
      {
        "id": "rep_cycle_20",
        "type": "Cycle",
        "exitCondition": "Unacceptable toxicity",
        "sourceText": "until unacceptable \ntoxicity"
      },
      {
        "id": "rep_cycle_21",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until death"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "minObservations": 2,
        "exitCondition": "death from any cause within 3 weeks",
        "sourceText": "Mean and mean changes from baseline score (by cycle) in all the subscales of the EORTC QLQ-C30 and QLQ-HCC18"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "interval": "P21D",
        "minObservations": 2,
        "exitCondition": "death from any cause within 3 weeks",
        "sourceText": "TTD maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks"
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "P0D",
        "minObservations": 2,
        "sourceText": "Timing for Vital Sign Measurements for First and Subsequent Infusions"
      },
      {
        "id": "rep_llm_4",
        "type": "Interval",
        "startOffset": "P0D",
        "minObservations": 2,
        "sourceText": "Serum concentration of atezolizumab at specified timepoints"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "TREATMENT",
          "SAFETY_FOLLOW_UP",
          "SURVIVAL_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Treatment Discontinuation Visit",
          "Cycle 1 Day 1",
          "Screening",
          "Safety Follow-up Visit",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Adverse Event requiring discontinuation', 'path': ['STUDY_TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'Withdrawal of consent', 'path': ['PATIENT_DISCONTINUATION_FROM_STUDY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Serum Sample",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medication",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Laboratory Test",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; SINGLE signals: 3"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 2"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Imaging",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Tissue Sample",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Overall Survival (OS) Analysis",
        "executionType": "Window",
        "rationale": "Described as pre-planned interim analyses and subsequent analyses once statistical significance is reached, indicating a continuous monitoring window."
      },
      {
        "activityId": "Management of Dermatologic Events",
        "executionType": "Episode",
        "rationale": "Guidelines for Grade 3 events or Stevens-Johnson syndrome involve conditional workflows and decision points based on the severity of the reaction."
      },
      {
        "activityId": "Management of Infusion-Related Reactions",
        "executionType": "Episode",
        "rationale": "Requires specific management actions and interventions triggered by the occurrence and grade of the reaction."
      },
      {
        "activityId": "Screening for Severe Infection",
        "executionType": "Single",
        "rationale": "Exclusion criteria assessment performed within 4 weeks prior to initiation of study treatment to determine eligibility."
      },
      {
        "activityId": "Safety Plan Monitoring",
        "executionType": "Recurring",
        "rationale": "Ongoing assessment of patient safety and active infections throughout the study participation period."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization.",
        "footnoteId": "fn_1",
        "structuredCondition": "timing.after(randomization, P3D)",
        "appliesToActivityIds": [
          "First Dosing",
          "Cycle 1 Day 1"
        ],
        "sourceText": "a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization."
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Written informed consent can be obtained up to 30 days prior to study entry.",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.before(study_entry, P30D)",
        "appliesToActivityIds": [
          "Informed Consent"
        ],
        "sourceText": "b. Written informed consent can be obtained up to 30 days prior to study entry."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.after(last_dose, P30D)",
        "appliesToActivityIds": [
          "Follow-up Visit"
        ],
        "sourceText": "c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may be obtained ≤ 96 hours before Day 1 of each cycle.",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
        "appliesToActivityIds": [
          "ECOG Performance Status",
          "Limited physical examination",
          "Local laboratory assessments",
          "PROs"
        ],
        "timingConstraint": "PT96H",
        "sourceText": "g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "i. Tumor assessments will be performed at baseline, every 6 weeks (± 1 week) for the first 54 weeks.",
        "footnoteId": "fn_5",
        "structuredCondition": "frequency.interval(P6W, P1W).duration(P54W)",
        "appliesToActivityIds": [
          "Tumor assessments"
        ],
        "sourceText": "i. Tumor assessments will be performed at baseline, every 6 weeks (± 1 week) for the first 54 weeks."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_before",
        "text": "z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administration.",
        "footnoteId": "fn_6",
        "structuredCondition": "sequence.before(study_treatment_administration, local_lab_review)",
        "appliesToActivityIds": [
          "Local laboratory assessments",
          "Study treatment administration"
        ],
        "sourceText": "z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administra"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Co-Primary: Overall Survival (OS)",
        "endpointType": "Primary",
        "inputs": [
          "date of randomization",
          "date of death",
          "last date known alive",
          "geographic region",
          "macrovascular invasion/extrahepatic spread",
          "baseline alpha-fetoprotein (AFP)"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until death or data cutoff"
        },
        "algorithm": "OS = date of death - date of randomization; if alive, censor at last date known alive; if no post-baseline info, censor at randomization",
        "successCriteria": "Statistically significant difference between treatment arms based on a 2-sided log-rank test at a significance level of 0.048",
        "sourceText": "Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last "
      },
      {
        "id": "ep_2",
        "name": "Co-Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "date of randomization",
          "date of disease progression",
          "date of death",
          "IRF assessment (RECIST v1.1)"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until progression or death"
        },
        "algorithm": "Time from randomization to the first occurrence of disease progression (as determined by IRF per RECIST v1.1) or death from any cause, whichever occurs first",
        "successCriteria": "Statistically significant difference between treatment arms based on a 2-sided log-rank test at a significance level of 0.002",
        "sourceText": "The primary efficacy objective for this study is to evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of O"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Mean Change from Baseline in EORTC QLQ-C30 Subscales",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "EORTC QLQ-C30 subscale scores"
        ],
        "derivationRule": "Post-baseline score at specific cycle - Baseline score",
        "baselineDefinition": "Baseline score (pre-treatment)",
        "baselineVisit": "Baseline",
        "analysisWindow": "By cycle",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_2",
        "name": "Mean Change from Baseline in EORTC QLQ-HCC18 Subscales",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "EORTC QLQ-HCC18 subscale scores"
        ],
        "derivationRule": "Post-baseline score at specific cycle - Baseline score",
        "baselineDefinition": "Baseline score (pre-treatment)",
        "baselineVisit": "Baseline",
        "analysisWindow": "By cycle",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_3",
        "name": "Clinically Meaningful Change in Select Scales",
        "variableType": "Categorical",
        "sourceVariables": [
          "QLQ-C30 (GHS/QoL, physical function, role function, appetite loss, diarrhea, fatigue, pain)",
          "QLQ-HCC18 (fatigue, jaundice, pain)"
        ],
        "derivationRule": "Proportion of patients meeting a predefined threshold for clinically meaningful change",
        "baselineDefinition": "Baseline score (pre-treatment)",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Proportion"
      },
      {
        "id": "dv_4",
        "name": "Time to Deterioration (TTD) - Symptoms",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "QLQ-C30 (appetite loss, diarrhea, fatigue, pain)",
          "QLQ-HCC18 (jaundice, fatigue, pain)"
        ],
        "derivationRule": "Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death within 3 weeks",
        "baselineDefinition": "Baseline score (pre-treatment)",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Days/Months"
      },
      {
        "id": "dv_5",
        "name": "Time to Deterioration (TTD) - Function/HRQoL",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "QLQ-C30 (HRQoL/GHS, physical function, role function)"
        ],
        "derivationRule": "Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death",
        "baselineDefinition": "Baseline score (pre-treatment)",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Days/Months"
      },
      {
        "id": "dv_6",
        "name": "ADA Status",
        "variableType": "Categorical",
        "sourceVariables": [
          "Anti-drug antibodies (ADAs)"
        ],
        "derivationRule": "Presence of ADAs during the study relative to the presence of ADAs at baseline",
        "baselineDefinition": "Presence of ADAs at baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Positive/Negative"
      },
      {
        "id": "dv_7",
        "name": "Health Utility and VAS Scores",
        "variableType": "Custom",
        "sourceVariables": [
          "EQ-5D-5L questionnaire"
        ],
        "derivationRule": "Calculation of utility scores based on EQ-5D-5L responses and Visual Analog Scale (VAS) scores",
        "baselineDefinition": "Baseline assessment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Index score / 0-100 scale"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Treatment",
        "Safety Follow Up",
        "Survival Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Safety Follow Up",
          "trigger": "Progress to Safety Follow Up"
        },
        {
          "fromState": "Safety Follow Up",
          "toState": "Survival Follow Up",
          "trigger": "Progress to Survival Follow Up"
        },
        {
          "fromState": "Survival Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Treatment": "TREATMENT",
        "Safety Follow Up": "SAFETY_FOLLOW_UP",
        "Survival Follow Up": "SURVIVAL_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Atezolizumab",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1200.0,
            "unit": "mg"
          },
          {
            "amount": 400.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "3 weeks",
        "doseModifications": [
          "Dose management for Grade 3 dermatologic events",
          "Management for Stevens-Johnson syndrome or toxic epidermal necrolysis",
          "Management for Hepatic Events"
        ],
        "sourceText": "or metastatic HCC who have received no prior systemic treatment. This study will enroll approximately 480 patients randomized in a 2:1 ratio to one of two treatment arms:  Arm A (experimental arm): A"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Sorafenib",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 400.0,
            "unit": "mg"
          },
          {
            "amount": 1200.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "3 weeks",
        "doseModifications": [
          "Dose reduction for treatment-emergent toxicities"
        ],
        "sourceText": "reatment arms:  Arm A (experimental arm): Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W; dosed in 3-week cycles) and bevacizumab 15 mg/kg Q3W (dosed in 3-week cycles)  Arm B (control arm): Sor"
      },
      {
        "id": "dosing_3",
        "treatmentName": "Patients received",
        "frequency": "Q3W",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1200.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "sourceText": "with metastatic cancer. Arm A is designed to test the combination of atezolizumab and bevacizumab in patients with locally advanced or metastatic HCC who have not received prior systemic therapy. Pati"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Bevacizumab",
        "frequency": "Q3W",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 15.0,
            "unit": "mg/kg",
            "description": "Weight-based dose"
          }
        ],
        "durationDescription": "Until loss of clinical benefit or unacceptable toxicity",
        "doseModifications": [
          "Dose modifications for toxicity as per protocol guidelines"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Negative HIV test at screening  Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV)"
      },
      {
        "id": "visit_1",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Screening",
        "sourceText": "Patients discovered to have 2proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate 1 g of protein in 24 hours."
      },
      {
        "id": "visit_3",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "heterosexual intercourse) or use contraceptive methods with a failure rate of 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the"
      },
      {
        "id": "visit_4",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Measurable disease, per RECIST v1.1, must be present outside the CNS. – The patient has no history of intracranial hemorrhage or spinal cord hemorrhage."
      },
      {
        "id": "visit_5",
        "visitName": "eot",
        "targetDay": null,
        "windowBefore": 28,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "The patient has not undergone stereotactic, whole-brain radiotherapy, and/or neurosurgical resection within 28 days prior to initiation of study treatment. –"
      },
      {
        "id": "visit_6",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "End of Study The end of this study is defined as the date when the last patient, last visit (LPLV) occurs (i.e., last patient in the global and extended China enrollment phases combined) or safety"
      },
      {
        "id": "visit_9",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last "
      },
      {
        "id": "visit_7",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "follow-up is received from the last patient (global and extended China enrollment phases combined), whichever occurs later. In addition, the Sponsor may decide to terminate the study at any time."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "geographic region (asia excluding japan vs"
        },
        {
          "id": "strat_llm_1",
          "name": "Geographic region",
          "categories": [
            "Asia excluding Japan",
            "rest of world"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Macrovascular invasion and/or extrahepatic spread",
          "categories": [
            "presence",
            "absence"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Baseline α-fetoprotein",
          "categories": [
            "<400 ng/mL",
            "≥400 ng/mL"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_4",
          "name": "Eastern Cooperative Oncology Group Performance Status",
          "categories": [
            "0",
            "1"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Atezolizumab—F. Hoffmann-La Roche Ltd\n4/Protocol YO40245, Version 6\n3.3.7\nRationale for Stratification...................................................... 47\n3.3.7.1\nGeographic Region..............."
    }
  }
}